Kornimate/medical-research-clean huggingface dataset:
a prospective, multicentre, open-label randomised controlled study to investigate the effectiveness of pamidronate in the prevention of bone loss in de novo renal transplant patients.

Conditions: Bone Loss

Summary: the purpose of the study was to evaluate the effect of pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a ciclosporin a and glucocorticoid based immunosuppressive regimen.


Eligibility criteria:
inclusion criteria: 1. first or second kidney transplant recipients, aged 18-75 years, pth \> 150 pg/ml 2. de novo patients scheduled to receive ciclosporin a and prednisolone based immunosuppression. exclusion criteria: 1. previous or current bone disease unrelated to end stage renal failure. 2. patients with pth \< 150pg/ml who may be at risk of adynamic bone disease. 3. treatment at any time with a bisphosphonate. 4. d. calcitonin treatment during the previous month. 5. malignancy (current or history within last 5 years) 6. pregnancy or lactation, or women of childbearing potential unwilling to use an effective form of contraception for the 12 month duration of the study. protocol-defined inclusion/exclusion criteria may apply.

Keywords: renal transplant, pamidronate, ciclosporin, ciclosporin a, steroids, bone mineral density, fracture rates immunosuppressive regimen
retrospective & prospective observational study of patients with immune (idiopathic) thrombocytopenic purpura (itp)

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura

Summary: this is a multi-center prospective observational descriptive study complemented by a retrospective chart review. patients diagnosed with itp and currently treated for itp by a hematologist or hematologist-oncologist will be recruited from community-based clinics and academic/referral centers. they will be followed prospectively for a period of 12 months. at inception, participants' charts will also be reviewed from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever is less.

time perspective: 12 months prospective chart review study with a retrospective chart review for a period up to 36 months from the start of the study, since the date of diagnosis for itp.

Eligibility criteria:
inclusion criteria: * has a diagnosis of itp according to the american society of hematology guidelines (george et al., 1996). * is equal to or greater than 18 years of age. * is willing and able to complete a series of questionnaires. * before any study-specific procedure, the appropriate written informed consent must be obtained. exclusion criteria: * participated in clinical trial(s) during the past 36 months. * is considering participation in a clinical trial within the next 12 months.

Keywords: thrombocytopenia chart review platelet retrospective prospective non-interventional health resource utilization (hru) quality of life (qol) immune thrombocytopenic purpura (itp) idiopathic thrombocytopenic purpura (itp) immune (idiopathic) thrombocytopenic purpura (itp) observational
gemcitabine, bevacizumab and erlotinib in pancreatic cancer

Conditions: Pancreatic Cancer; Adenocarcinoma of the Pancreas

Summary: the main purpose of this study is to learn whether or not the combination of gemcitabine, bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic cancer. bevacizumab is a new anti-cancer drug. it is an antibody that works to slow or stop cell growth in cancerous tumors by decreasing the blood supply to the tumors. it is approved by the fda for the treatment of colorectal cancer but is still considered investigational for treating pancreatic cancer.

* participants will receive study treatment as an outpatient. the study treatment will be given in time periods called cycles. each treatment cycle will be 28 days. * gemcitabine will be given intravenously on days 1, 8, and 15 (once per week for the first three weeks) of the treatment cycle. * bevacizumab will be given intravenously on days 1 and 15 (once every 2 weeks) of the treatment cycle. * erlotinib will be taken orally every day of the treatment cycle. * participants will see the doctor or nurse practitioner every week for the first 28 days of treatment. during all of the following cycles, they will see the doctor or nurse practitioner on day 1 and day 15 of each cycle. * each 4-week cycle can be repeated until the participant or the doctor decided that they should be removed from the study.

Eligibility criteria:
inclusion criteria: * previously untreated patients with unresectable or metastatic adenocarcinoma of the pancreas * ecog performance status 0-2 * 18 years of age or older * radiographically measurable disease * expected survival of at least 4 months * creatinine of \</= 2.0 * adequate hepatic function * adequate hematopoietic function * use of effective means of contraception in subjects of child-bearing potential exclusion criteria: * warfarin anticoagulation * prior treatment with a tyrosine kinase inhibitor, egfr inhibitor, or vegf inhibitor * coexistent malignant disease * current or recent (within 4 weeks) participation in a clinical trial * pregnancy * documented invasion of adjacent organs or major blood vessels * blood pressure of \> 150/100mmhg * unstable angina * nyha grade ii or greater congestive heart failure * history of myocardial infarction or stroke within 6 months * clinically significant peripheral vascular disease * evidence of bleeding diathesis of coagulopathy * presence of cns or brain metastases * major surgical procedure, open biopsy, or significant traumatic event within 28 days * minor surgical procedures, fine needle aspirations or core biopsies within 7 days * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months * serious non-healing wound, ulcer or bone fracture
igf1 generation test

Conditions: Growth Hormone Deficiency

Summary: to assess the predictive value of the short term igf-1 stimulation test, based on igf-1 changes, on the 24 months growth response to 2 different doses of gh in patients with conventional gh deficiency.


Eligibility criteria:
inclusion criteria: * male or female aged of more than 4 years. * ghd defined as a peak gh level \< 20 mui/ml at two different pharmacological gh provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the french health authorities exclusion criteria: * previous treatment with gh * ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy
total corneal astigmatism prevalence in cataract patients

Conditions: Cataract

Summary: the purpose of this study is to report the prevalence data for total corneal astigmatism (tca) in cataract surgery candidates.

the purpose of this retrospective study is to report the prevalence data for total corneal astigmatism (tca) in cataract surgery candidates. preoperative biometric data of all the patients who underwent cataract surgery in the department of ophthalmology, peking university third hospital, from january 2019 to may 2023, were collected and analyzed. data sets with incomplete biometric data were excluded.

Eligibility criteria:
inclusion criteria: * patients who underwent cataract surgery in the department of ophthalmology, peking university third hospital from january 2019 to may 2023. exclusion criteria: * incomplete biometric data .

Keywords: cataract astigmatism prevalence
a study investigating the pharmacokinetics of fv-100 with and without ritonavir in healthy volunteers

Conditions: Acute Herpes Zoster

Summary: this study is designed to evaluate the potential for a pk drug-drug interaction between fv-100 and ritonavir. the study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.


Eligibility criteria:
inclusion criteria: * capable of giving written informed consent * non-tobacco user for at least 3 months prior to selection * healthy on the basis of physical examination, medical history, ecg and clinical laboratory testing at screening exclusion criteria:(must not meet the following) * infected with hepatitis a, b, c, or hiv * history of or any current medical condition which could impact safety of the participant * a positive urine drug test * consumption of more than 2 units of alcoholic beverages per day or more than 14 per week * received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 half-lives before the planned start of treatment or prior treatment with fv-100 * subjects who have used any drugs or substances known to inhibit or induce cytochrome(cyp) p450 enzymes and/or p-gp within 28 days prior to the first dose and throughout study * subjects who have, within 2 weeks prior to the first dose of study drug, ingested grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family or charbroiled meats
high flow nasal cannula hfnc in covid-19 patients

Conditions: SARS-CoV Infection; SARS (Severe Acute Respiratory Syndrome)

Summary: many non-invasive ventilatory choices are available for covid-19 patient who are having mild to moderate respiratory distress and their use will decrease the chance of icu admission, intubation and mechanical ventilation in severe cases of covid-19. however, all these respiratory supports and oxygen supply devices are aerosol generating and their selection should be precised enough to control nosocomial spread. high flow nasal cannula hfnc is a device that delivered the warmed and humid air on high flow rate through nose. it is used to treat severe respiratory distress in covid-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen. in acute respiratory failure hfnc is proven to be very effective and it also reduced the need of mechanical ventilation in severe patients. apart from the supply of oxygen, hfnc generating positive airway pressure and decreasing the rebreathing from anatomical dead space. prone position is also a save therapy and has been proven to be effective for refractory hypoxia by increasing tidal volume, oxygenation and diaphragmatic functions in ards patients. recent studies showed that prone positioning and hfnc might avoid the prerequisite of intubation in moderate to severe patients of ards and as a result it decreases the nosocomial infection in physicians who are doing these aerosol generating procedures.

this is observational single-center study, that will be done at lahore general hospital in which 95 beds are allocated for covid-19 patients including icus and hdus. ethical approval will be obtained from research ethical committee of lahore general hospital, lahore. informed consent will be obtained from all patients who will agree to publish their data in this research. we will protect patient's privacy and obey with the helsinki declaration.

Eligibility criteria:
inclusion criteria: * all patients of \> 18 years of ages, males and females who will be diagnosed covid-19 positive by rt-pcr with moderate illness. * patients having classical radiological lesions of covid-19 on x-ray chest or hrct chest. * respiratory rate \> 30/ min and not responding to non-rebreather masks. * covid-related pneumonia requiring non-invasive ventilatory support (high-flow nasal cannula, and / or non-invasive ventilation and / or cpap) exclusion criteria: * inability to provide consent; * severe respiratory failure requiring invasive ventilatory support; * indication of immediate tracheal intubation * significant acute progressive circulatory insufficiency * impaired alertness, confusion, restlessness * chest trauma or other contraindication to prone position * pneumothorax * nasal blockade * unable to tolerate high flow oxygen

Keywords: covid-19 high flow nasal cannula hfnc clinical outcome
effects of music therapy in controlling symptoms in patients with aml and undergoing hsct

Conditions: Acute Myeloblastic Leukemia; Hematopoietic Stem Cell Transplantation

Summary: the goal of this clinical trial is to test passive music therapy in patients receiving induction chemotherapy for an acute myeloblastic leukemia or undergoing an hematopoietic stem cell transplantation. the main questions it aims to answer are: - can music therapy control physical and psychological symptoms and improve the mood and quality of life of these patients? participants will be randomly assigned to the control and experimental group. patients included in both groups will complete weekly mood and quality of life questionnaires. those included in the experimental group will also complete daily symptom burden questionnaires before and after listening to a music therapy session. researchers will confirm if the experimental group improves their symptoms after the music therapy session and will compare both groups to see if there are differences in mood and quality of life.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old. * patients receiving induction chemotherapy for a newly diagnosed acute myeloblastic leukemia (except for acute promyelocytic leukemia). * patients undergoing autologous or allogeneic stem cell transplantation. * being able to understand and read spanish properly. * basic computer skills. exclusion criteria: * moderate-severe hearing impairment (unilateral or bilateral). * past history of psychiatric disorders. * performance status: ecog ≥ 3.

Keywords: acute myeloblastic leukemia hematopoietic stem cell transplantation music therapy symptom control
buteyko method for asthmatic children with mouth breathing

Conditions: Asthma; Mouth Breathing

Summary: to assess the effectiveness of the buteyko method as an adjunct therapy in the treatment of asthmatic children with mouth breathing.


Eligibility criteria:
inclusion criteria: * children from 7 up to 12 years old with asthma diagnose * regular inhaled corticosteroids with no change in dose in the preceding 4 weeks. * children cannot present: other respiratory disease (such as cystic fibrosis, bronchiectasis, and tuberculosis), retinal detachment, hypertensive crisis, congenital heart defect, pulmonary edema, history of lobectomy or lung segmentectomy, respiratory infections 15 days prior to the evaluations. exclusion criteria: * children that are not able to perform some of the necessary procedures, give up participating in the research and present acute symptoms of respiratory tract during the assessments.

Keywords: child breathing exercises
italian translation and transcultural validation of frenchay activity index and walking handicap classification in stroke

Conditions: Stroke Sequelae

Summary: this study is aimed at providing an italian version of two assessment tools for participation in stroke patients, the frenchay activity index (fai) and the walking handicap classification (whc) by a standardized translation and transcultural validation protocol. the protocol includes a pre-test of the italian version on ten patients, a final revision, and a validation on a sample of 60 stroke patients.

this study is aimed at providing an italian version of two tools to assess participation in stroke patients, the frenchay activity index (fai) and the walking handicap classification (whc). these tools have been recently indicated for the assessment of participation in stroke patients by the italian association of physical and rehabilitation medicine (minimal stroke assessment protocol - pmic2); they are currently used in italian research and clinical settings, but no official translation exists. the process requires a standardized translation protocol, including forward and backward translation, using a multistep revision structure, to ensure conceptual and semantic equivalence. the validation process includes a pilot evaluation of on 10 individuals post-stroke admitted to the neurological rehabilitation unit, foundation don gnocchi scientific institute, and a validation on a sample of 60 stroke patients including reliability, internal consistency and concurrent validity assessment of the translated version against the sickness impact profile (sip) - italian version and the rivermead mobility index (rmi) - italian version, respectively

Eligibility criteria:
pre-test: consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the neurological rehabilitation unit, foundation don gnocchi scientific institute. inclusion criteria: * age 18-90; * stroke occurred within 3 months from enrollment; * clinical stability (sic = 0). exclusion criteria: * stroke recurrence; * visual and / or hearing disorders; * cognitive decline (mmse \<21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools validation: recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the neurological rehabilitation unit, foundation don gnocchi scientific institute- inclusion criteria: * age 18-90, * stroke occurred within 8 months from enrollment; * clinical stability (sic = 0). criteria for carrying out the interview with a proxy. if a proxy is not available, the patient is excluded: * visual and / or hearing disorders; * cognitive decline (mmse \<21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools.

Keywords: participation frenchay activity index walking handicap classification stroke rehabilitation
ablation index guided high power ablation for pulmonary vein isolation in patients with atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the investigators will compare the ablation time during pulmonary vein isolation of ablation index-guided high power ablation with those with conventional ablation. ablation time of conventional group will be used from optimum study. for secondary outcomes, acute outcomes of pulmonary vein isolation using two different strategies will be compared. during 1 year of follow-up in both groups, atrial fibrillation recurrence will be evaluated. the atrial fibrillation recurrence rate at 1 year after pulmonary vein isolation will be compared between the two groups. in addition, fluoroscopic time, procedure time, and complication rates for the high power ablation group will be compared with those with conventional power.

ablation index guided high power ablation will be performed in 70 patients with atrial fibrillation with prospectively and consecutively. a contact force-sensing catheter will be used. ablation will be performed with point-by-point technique using visitag automated annotation criteria as below; ablation index(ai) target: * anterior/roof : 450 ai * anterior near carina area : 500 ai * posterior/inferior/carina : 350 ai * posterior near carina area : 400 ai * area near esophagus :25w, 15sec or 300 ai (no further ablation if esophageal temperature increase more than 39°c) * interlesion distance ≤ 4.5mm visitagtm settings * 2.5mm stability range * 7 sec stability time * fot 25%, 3g force * tag size 2mm ablation parameters are preset as below; * rf power range: 40w at anterior/roof, 30w at posterior/inferior, 25w at near esophagus area (decrease power 5w by operator decision) * target contact force range: 10-20 g * flow rate: * 8 ml/min for stsf \< 30w * 15 ml/min for stsf ≥ 30w acute reconnection will be analysed according to predefined segments. subgroup analysis will be performed according to type of af. data of patients with paroxysmal atrial fibrillation and persistent atrial fibrillation will be analysed separately, and investigate whether this new ablation strategy is effective in both group of patients. to compare outcomes with opitmum phase 2 study, the proportion of patients with paroxysmal and persistent atrial fibrillation would be 75% and 25%. therefore, 53 patients with paroxysmal atrial fibrillation and 17 patients with persistent atrial fibrillation will be enrolled in this study.

Eligibility criteria:
inclusion criteria: * patients with symptomatic paroxysmal or persistent af who failed anti-arrhythmic agents exclusion criteria: * patients who had previous ablation for af * patients with left atrial diameter more than 50 mm * inability or unwillingness to receive oral anticoagulation with a vitamin k antagonist (vka) or non-vka (noac) agent * known severe left ventricular systolic dysfunction (ejection fraction \<35%) * pregnancy
cartography of functional and epileptic cerebral areas by functional mri and electroencephalography in epileptic patients before and after surgery

Conditions: Epilepsy

Summary: exploring the reorganization (plasticity) of neuroanatomic networks associated with language and memory in patients with left (or dominant hemisphere) temporal lobe epilepsy using functional mri (fmri)

the purpose of this study is to explore the reorganization of neuroanatomic networks associated with language and memory in adult patients with temporal lobe epilepsy (elt). by using functional mri, patients will be examined before and after surgery. cerebral plasticity, defined in terms of intrinsic variables such as the topography of the activated regions, will be explored according to some extrinsic factors such as the age at onset of crises (before or after 5-6 years), whether or not hippocampal sclerosis, hemispheric predominance of language (left or right).

Eligibility criteria:
inclusion criteria: * epileptic patients * medical exam before inclusion * social security affiliation * pharmaco-resistant epilepsy exclusion criteria: * mri contraindication * pregnant women * breastfeeding mothers * person under tutorship
dry needling for treating spasticity in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of the study is to evaluate the efficacy of dry needling (dn) in the treatment of spasticity in patients with multiple sclerosis (ms). \[participants and methods\] participants with ms, with no evidence of a relapse in the last four weeks and with an edss (expanded disability sta- tus scale) greater than 2.5 points (related with pyramidal score) were recruited. dn was performed in lower limbs for 12 consecutive sessions and evaluated with: edss (pyramidal item), time up and go (tug), 25 foot, 9hold peg test (9hpt) and the improvement or not in the quality of life (msqol54) was verified before and after treatment. a follow up visit was carried out to assess improvement.


Eligibility criteria:
inclusion criteria: * being a patient diagnosed with multiple sclerosis. * being over 18 years of age and less than or equal to 60 years of age. * having a score equal to or greater than 2 in the edss. * they need to have a measurement in the following functional systems: p (pyramidal) \>2, ct (brainstem), gait \>2 and sphincter \>2. * they need to present hypertonia or contractures of the muscles selected for the dry needling, the pain expressed by the patients must be a consequence of spastic processes, have hourly availability to receive therapies and not have needle phobias. exclusion criteria: * having a disease associated with multiple sclerosis that is incompatible with dry needling. * being in relapse, or having suffered it in the thirty days prior to starting the treatment. program or taking medications that are contraindicated with the technique applied in the study, (oral anticoagulants.)

Keywords: dry needling, multiple sclerosis, physiotherapy